Our Pricing

Why Is Wegovy Dose Lower Than Mounjaro? Understanding Wegovy Dose vs Mounjaro Dose

Many UK patients ask why the Wegovy dose vs Mounjaro dose differs so significantly, especially when both medications target weight loss through GLP-1 receptor activity. Wegovy (semaglutide) reaches a maximum maintenance dose of 2.4 mg weekly, whilst Mounjaro (tirzepatide) escalates to 15 mg weekly — a seemingly higher numerical dose that reflects fundamental differences in molecular structure, receptor binding, and pharmacokinetics rather than superior potency[1]. At Cured Pharmacy, our clinical team frequently guides patients through these dosing distinctions to ensure safe, evidence-based treatment selection under UK prescriber supervision.

Different Mechanisms Explain the Wegovy Dose vs Mounjaro Dose Gap

The apparent disparity in Wegovy dose vs Mounjaro dose stems from their distinct pharmacological profiles. Semaglutide (Wegovy) is a selective GLP-1 receptor agonist with approximately 94% structural homology to native human GLP-1, engineered for once-weekly subcutaneous administration[1]. Tirzepatide (Mounjaro), by contrast, is a dual GIP/GLP-1 receptor agonist — the first in its class — requiring higher milligram dosing to achieve balanced activation of both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways[2].

Clinical trial data demonstrate that these medications cannot be compared on milligram-for-milligram terms. The STEP 1 trial showed semaglutide 2.4 mg produced mean weight loss of 14.9% over 68 weeks, whilst the SURMOUNT-1 trial recorded tirzepatide 15 mg achieving 20.9% mean weight reduction over 72 weeks[1][2]. However, molecular weight, receptor affinity, and half-life all differ substantially, making direct dose comparison scientifically invalid. Our superintendent pharmacist Tarun Kumar emphasises that prescribers select treatment based on individual patient factors, not numerical dose size.

Wegovy Dose vs Mounjaro Dose Titration Schedules in the UK

Understanding the Wegovy dose vs Mounjaro dose titration protocols is essential for patient safety and tolerability. Wegovy follows a five-month escalation: 0.25 mg weekly for four weeks, then 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg maintenance dose — each step lasting four weeks to minimise gastrointestinal side effects[3]. This gradual approach allows the body to adapt to increasing GLP-1 receptor stimulation, reducing nausea and vomiting incidence observed in clinical trials.

Mounjaro employs a similar stepwise titration but across a different dose range: starting at 2.5 mg weekly, increasing every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg weekly[4]. The higher numerical doses reflect tirzepatide's dual-agonist mechanism requiring greater mass to achieve therapeutic GIP and GLP-1 receptor occupancy. UK prescribers may pause escalation at any tolerated dose if weight loss targets are met, meaning not all patients require maximum dosing.

Why Slower Titration Improves Wegovy Dose vs Mounjaro Dose Tolerability

Both medications mandate gradual dose escalation because abrupt GLP-1 receptor activation triggers significant gastrointestinal adverse effects. Meta-analyses confirm that nausea affects approximately 44% of semaglutide users and 34% of tirzepatide users when titration protocols are followed correctly[3][4]. Skipping dose steps or accelerating the schedule substantially increases discontinuation rates, undermining long-term weight management outcomes. Cured Pharmacy's clinical assessment process ensures patients understand their prescribed titration pathway before commencing treatment, subject to UK prescriber approval.

Clinical Efficacy Beyond the Wegovy Dose vs Mounjaro Dose Numbers

When evaluating Wegovy dose vs Mounjaro dose for weight loss efficacy, the evidence base extends far beyond milligram quantities. The STEP clinical programme (eight trials, over 10,000 participants) demonstrated semaglutide 2.4 mg produced consistent weight reductions between 10.9% and 17.4% across diverse patient populations, including those with type 2 diabetes and cardiovascular comorbidities[1]. Participants also experienced improvements in waist circumference, blood pressure, and lipid profiles independent of diabetes status.

The SURMOUNT trial series for tirzepatide showed dose-dependent weight loss, with the 15 mg cohort achieving the highest mean reduction of 20.9%, compared to 15.0% at 10 mg and 19.5% at 12.5 mg[2]. However, individual response varies considerably — some patients achieve target weight loss on Wegovy's lower numerical dose, whilst others may require Mounjaro's dual-agonist mechanism. UK prescribers assess baseline BMI, comorbidities, previous weight loss attempts, and patient preference when selecting between these medications, both available at Cured Pharmacy from £124.99 for Wegovy.

Real-World Wegovy Dose vs Mounjaro Dose Outcomes in UK Practice

Post-marketing surveillance and real-world evidence studies in the UK confirm that clinical trial efficacy translates to routine practice when medications are prescribed appropriately. A 2023 retrospective cohort study of 2,400 UK patients found 68% maintained at least 10% weight loss at 12 months on semaglutide 2.4 mg, with adherence rates of 74%[5]. Comparable real-world data for tirzepatide remain limited given its more recent UK launch, though early registry data suggest similar or marginally superior retention rates at higher doses. Our clinical team at Cured Pharmacy monitors patient progress through follow-up consultations, adjusting treatment plans in collaboration with prescribers to optimise outcomes.

Safety Profiles Across the Wegovy Dose vs Mounjaro Dose Spectrum

Safety considerations are paramount when comparing Wegovy dose vs Mounjaro dose regimens. Both medications share a common adverse effect profile dominated by gastrointestinal symptoms: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort[3][4]. These effects are dose-dependent and typically peak during titration phases, improving as patients acclimate to each new dose level. Serious adverse events remain rare but include pancreatitis (0.2-0.4% incidence), gallbladder disease, and hypoglycaemia when combined with insulin or sulphonylureas.

The MHRA and NICE guidance for both medications emphasise the importance of patient selection, contraindication screening, and ongoing monitoring. Wegovy and Mounjaro are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, based on rodent study findings[1][2]. UK prescribers at Cured Pharmacy conduct comprehensive medical assessments before initiating treatment, ensuring patients understand potential risks and report concerning symptoms promptly. All prescription medications require clinical approval by a UK-registered prescriber following online consultation.

Cost Considerations in the Wegovy Dose vs Mounjaro Dose Decision

Financial factors significantly influence the Wegovy dose vs Mounjaro dose choice for many UK patients, particularly as neither medication is routinely funded by the NHS for weight management outside specialist tier 3 services. At Cured Pharmacy, Wegovy is available from £124.99 per month, offering competitive UK pricing with transparent upfront costs before consultation. Mounjaro pricing starts from £124.99, reflecting its newer market entry and dual-agonist formulation. Patients should consider total treatment duration — typically 12-24 months for sustained weight loss — when evaluating affordability.

Both medications require ongoing prescription, meaning cost accumulates over the treatment course. However, clinical data suggest that achieving and maintaining significant weight loss reduces long-term healthcare expenditure through decreased cardiovascular events, reduced diabetes progression, and lower rates of obesity-related complications[6]. Our team at Cured Pharmacy provides transparent pricing and accepts the discount code Weightlossnew for £20 off first orders, ensuring patients access genuine UK-licensed medications at the lowest guaranteed prices without hidden consultation fees.

Insurance and NHS Coverage for Wegovy Dose vs Mounjaro Dose

Currently, NHS England restricts semaglutide 2.4 mg (Wegovy) to specialist weight management services for patients with BMI ≥35 kg/m² plus comorbidities, following NICE TA875 guidance published in March 2023[7]. Tirzepatide (Mounjaro) underwent NICE appraisal in 2024, with similar restricted access criteria anticipated. Most UK patients seeking these medications for weight loss access them through private prescription, either via online pharmacies like Cured Pharmacy or traditional GP private services. Private medical insurance coverage varies by policy, with some insurers covering GLP-1 medications for obesity when prescribed by a specialist consultant.

Choosing Between Wegovy Dose vs Mounjaro Dose: Clinical Guidance

The decision between Wegovy dose vs Mounjaro dose ultimately rests with the prescribing clinician, informed by patient-specific factors. Semaglutide may be preferred for patients with established cardiovascular disease, given the SELECT trial demonstrated 20% reduction in major adverse cardiovascular events in this population[8]. Tirzepatide may suit those who have not achieved adequate weight loss on GLP-1 monotherapy or require more pronounced glycaemic control alongside weight reduction, based on SURPASS trial subgroup analyses[2].

At Cured Pharmacy, our UK-registered clinical team conducts comprehensive online assessments in under three minutes, evaluating medical history, current medications, contraindications, and treatment goals. Patients receive personalised recommendations aligned with MHRA and NICE guidance, with prescriptions issued only when clinically appropriate. Both Wegovy and Mounjaro require commitment to lifestyle modification — structured nutrition plans and regular physical activity — to maximise efficacy and maintain weight loss after treatment cessation. Our pharmacists provide ongoing support throughout the treatment journey, ensuring safe, effective use of these powerful weight management medications.

Monitoring and Follow-Up for Wegovy Dose vs Mounjaro Dose Therapy

Regardless of whether patients commence Wegovy dose vs Mounjaro dose therapy, structured monitoring is essential. UK prescribing guidance recommends baseline assessment of weight, BMI, waist circumference, blood pressure, HbA1c (if diabetic), and lipid profile, with repeat measurements at 3, 6, and 12 months[7]. Treatment should be discontinued if patients fail to achieve at least 5% weight loss after 12 weeks on maintenance dose, or if intolerable adverse effects emerge. Cured Pharmacy facilitates follow-up consultations with UK prescribers to review progress, adjust dosing, and ensure ongoing treatment appropriateness, maintaining the highest standards of pharmaceutical care and patient safety.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Novo Nordisk Limited. [accessed 15 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 15 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Eli Lilly and Company Limited. [accessed 15 August 2026]
5. Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023). Real-world effectiveness of semaglutide for weight loss in overweight or obese patients: A retrospective cohort study. Obesity, 31(3), 727-731. [accessed 15 August 2026]
6. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wilding, J. P. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
8. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.